Archer-Daniels-Midland: We Are Again Right On Target, Slowdown Is Part Of Normalization
By Press Room
4 Mins read
Investment Thesis Review We initially covered Archer-Daniel-Midland at $89.41 in February this year with a “Sell” rating, and it subsequently realized an…
The Ensign Group, Inc. 2023 Q3 - Results - Earnings Call Presentation (NASDAQ:ENSG)
By Press Room
1 Mins read
This article was written by Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently…
Investment Perspective: Valuation and Growth Post Stock Drop While Coca-Cola’s (NYSE:KO) shares are off almost 14% since their highs earlier this year,…
The S&P 500 having made fresh lows in the past week has justified a continued decline in bullish sentiment per the latest…
British bank NatWest (NYSE:NWG) has had a tough week, selling off on the back of Q3 results from peers Barclays (BCS) and…
Canadian Solar Stock: EPS Outlook Plummeting On Solar Glut And China Risks (NASDAQ:CSIQ)
By Press Room
7 Mins read
2023 has been a particularly challenging year for the solar industry. The solar ETF (TAN) has lost 40% of its value this…
Metso Oyj (OTCPK:OUKPF) Q3 2023 Earnings Call Transcript October 27, 2023 6:00 AM ET Company Participants Juha Rouhiainen – VP, IR Pekka…
Carter’s, Inc. (NYSE:CRI) Q3 2023 Earnings Conference Call October 27, 2023 8:30 AM ET Company Participants Michael Casey – Chairman and Chief…
Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earnings (NASDAQ:APLS)
By Press Room
6 Mins read
Apellis Pharmaceuticals (NASDAQ:APLS), a standout player in the biotech sector, distinguishes itself with its novel C3 inhibitor technology, including their flagship compound,…
Ford Motor Company 2023 Q3 - Results - Earnings Call Presentation (NYSE:F)
By Press Room
1 Mins read
This article was written by Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently…